Sonus Pharmaceutical - Worst Pharma Stocks of 2007
Company: Sonus Pharmaceutical
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%
Details: Sonus was delivered a crushing blow in September. A Phase III study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to be less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with Sonus on the drug in October. The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.
Related Articles:
Sonus shares shattered on drug failure. Report
Sonus shares surge as FDA approves Phase III design. Report
More stories about Sonus Pharmaceutical
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
SHARE
WITH: